Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biweekly Romiplostim in Chronic ITP
NCT02338414Phase 2Unknown
- Sponsor
- Samsung Medical Center
- Start
- Jan 2015
- Primary completion
- Dec 2015
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Phase 2, open-label, single-arm trial of romiplostim in immune thrombocytopenia (ITP), sponsored by Samsung Medical Center. Primary endpoint: Efficacy of biweekly romiplostim (platelet counts >= 30 x 10^9/L) up to 24 weeks. Status: unknown.
02
Drugs
romiplostim
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT02338414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02338414.